Review: rosiglitazone increases risk of MI but does not differ from other drugs for CV death in type 2 diabetes
- PMID: 18063729
- DOI: 10.1136/ebm.12.6.169
Review: rosiglitazone increases risk of MI but does not differ from other drugs for CV death in type 2 diabetes
Comment on
-
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.N Engl J Med. 2007 Jun 14;356(24):2457-71. doi: 10.1056/NEJMoa072761. Epub 2007 May 21. N Engl J Med. 2007. PMID: 17517853
Publication types
LinkOut - more resources
Full Text Sources